OPEN ACCESS

Saudi Journal of Nursing and Health Care

Abbreviated Key Title: Saudi J Nurs Health Care
ISSN 2616-7921 (Print) |ISSN 2616-6186 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

Review Article

Innovations in HPV Vaccination Strategies: Bridging the Gap in Cervical Cancer Prevention

Manasa, H. S[1*], R. K. Mahadevaswamy[2], Renukadevi, D. N[3]

[1]Nursing Tutor, JSS School of Nursing, Mysore, Karnataka, India
[2]Senior Nursing Tutor, JSS School of Nursing, Mysore, Karnataka, India
[3]Principal, JSS School of Nursing, Mysore, Karnataka, India

DOI: https://doi.org/10.36348/sjnhc.2025.v08i02.002 | **Received:** 14.12.2024 | **Accepted:** 20.01.2025 | **Published:** 04.02.2025

***Corresponding author:** Manasa, H. S
Nursing Tutor, JSS School of Nursing, Mysore, Karnataka, India

Abstract

Cervical cancer remains a global health challenge, particularly in low- and middle-income countries (LMICs). Despite advancements in prevention and treatment, limited HPV vaccine coverage hampers cervical cancer elimination efforts. The HPV vaccine, recommended since 2006, has shown high efficacy, preventing up to 90% of HPV-related cancers. Recent innovations, such as single-dose vaccines, aim to enhance accessibility and affordability. This review highlights advancements in HPV vaccination strategies, focusing on equitable access, vaccine efficacy, and the path toward achieving the World Health Organization's goal of cervical cancer elimination.

Keywords: HPV vaccination, cervical cancer prevention, single-dose vaccine, vaccine accessibility, public health strategies.

INTRODUCTION

Cervical cancer ranks as the fourth most common cancer among women globally, with higher incidence rates in LMICs due to inadequate preventive measures. The World Health Organization (WHO) emphasizes vaccination as a cornerstone of cervical cancer prevention. Human papillomavirus (HPV), particularly types 16 and 18, accounts for 70% of cervical cancer cases worldwide. In India, cervical cancer leads in female cancer mortality, necessitating robust vaccination campaigns. This review delves into innovations in HPV vaccination strategies and their implications for bridging existing healthcare gaps.

Disease Spectrum

- HPV is a DNA virus of the Papillomaviridae family with over 100 identified serotypes, of which 15-20 are oncogenic.
- High-risk HPV types (16, 18) contribute significantly to cervical cancer, whereas low-risk types (6, 11) cause benign conditions like genital warts.
- The latency period from infection to cervical cancer development spans 15-20 years, highlighting the need for early vaccination.

HPV Vaccination: An Overview

- **Introduction:** Since its global recommendation in 2006, HPV vaccination has proven highly effective in reducing HPV-related diseases.
- **Types of Vaccines:**
  - **Cervarix:** Targets HPV-16, 18.
  - **Gardasil:** Targets HPV-6, 11, 16, 18.
  - **Gardasil 9:** Covers additional oncogenic HPV types.
  - **Cervavac:** India's indigenous vaccine for cost-effective prevention.

Efficacy and Benefits

- Prevents cancers of the cervix, vulva, vagina, anus, and oropharynx.
- Reduces the prevalence of genital warts and precancerous lesions.
- High efficacy in HPV-naïve populations; slightly reduced efficacy in individuals with prior HPV exposure.

Recent Advancements in HPV Vaccination

1. **Single-Dose Vaccines:**
   - Cost-effective and logistically feasible, particularly in LMICs.
   - Simplifies vaccination campaigns and improves compliance.

2. **Increased Coverage Goals:**
    - WHO aims to vaccinate 90% of girls aged 15 by 2030.
    - Targeted campaigns in schools and community settings are pivotal.

Adverse Effects

- Common side effects include pain at the injection site, headache, fever, and nausea.
- Most adverse effects are mild and self-limiting.

Vaccine Accessibility and Challenges

- **Target Population:** Girls aged 9-14 years are the primary beneficiaries, with catch-up vaccination available for older adolescents.

- **Barriers:**
    - Limited awareness in rural areas.
    - High costs and supply chain issues in LMICs.
    - Sociocultural stigma surrounding vaccines for sexually transmitted infections.

- **Solutions:**
    - Strengthened public health systems.
    - Subsidized vaccination programs.
    - Educational initiatives to address misconceptions.

CONCLUSION

HPV vaccination represents a transformative step in cervical cancer prevention. Recent advancements, including single-dose vaccines, enhance accessibility and affordability, addressing long-standing barriers in LMICs. Achieving WHO's vision of eliminating cervical cancer requires coordinated efforts among governments, healthcare professionals, and civil society. By prioritizing equitable vaccine delivery and fostering innovation, we can significantly reduce the global burden of cervical cancer and safeguard women's health.

REFERENCES

- International Agency for Research on Cancer, WHO. Globocan 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide.
- Sankaranarayanan, R. (2008). HPV Infection and Cervical Cancer Prevention in South Asia. *Vaccine*, 2008.
- Kaarthigeyan, K. (2012). Cervical cancer in India and HPV vaccination. *Indian Journal of Medical and Paediatric Oncology*, *33*(01), 7-12.
- Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., ... & Hutubessy, R. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. *The Lancet*, *395*(10224), 575-590.